Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

3.159 +0.099 (+3.23%)
Streaming Delayed Price Updated: 3:57 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 195,145
Open 3.060
Bid (Size) 3.150 (20)
Ask (Size) 3.170 (1)
Prev. Close 3.060
Today's Range 3.060 - 3.260
52wk Range 1.900 - 3.790
Shares Outstanding 9,362,444
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
Via The Motley Fool
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire

Performance

YTD
-4.7%
-4.7%
1 Month
+24.4%
+24.4%
3 Month
+30.0%
+30.0%
6 Month
+10.1%
+10.1%
1 Year
-12.3%
-12.3%

More News

Read More
Earnings Scheduled For August 7, 2025
Via Benzinga
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings
Via Benzinga
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
From Vistagen
Via Business Wire
Insights into VistaGen Therapeutics's Upcoming Earnings
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
Vistagen to Present at the BTIG Virtual Biotechnology Conference
From Vistagen
Via Business Wire
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
From Vistagen
Via Business Wire
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
From Vistagen
Via Business Wire
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Earnings Scheduled For June 17, 2025
Via Benzinga
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
From Vistagen
Via Business Wire
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
From Vistagen
Via Business Wire
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
From Vistagen
Via Business Wire
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
From Vistagen
Via Business Wire
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
From Vistagen
Via Business Wire
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
From Vistagen
Via Business Wire
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
From Vistagen
Via Business Wire
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
From Vistagen
Via Business Wire
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
From Vistagen
Via Business Wire
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
From Vistagen
Via Business Wire
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?
Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?
Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?
The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market
What is the current price of Vistagen Therapeutics, Inc. - Common Stock?
The current price of Vistagen Therapeutics, Inc. - Common Stock is 3.159
When was Vistagen Therapeutics, Inc. - Common Stock last traded?
The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 08/22/25 03:57 PM ET
What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?
The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 29.57M
How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?
Vistagen Therapeutics, Inc. - Common Stock has 30M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.